Open access
Survival Outcomes With Cadonilimab Versus PD‐(L)1 Therapy in Front‐Line Gastric Cancer: A Network Meta‐Analysis
Zi-Kun Yu
Jia-Hong Yi
Ju Xue
Yu-Che Huang
Yue Zhao
Chang Jiang
Chen-Xi Yin
Biao Xia
Yi-Xin Zhou
Wen-Zhuo He
Liang-Ping Xia
Medicine
Abstract
The FDA Oncologic Drugs Advisory Committee (ODAC) highlighted that the risk–benefit profile for patients with low PD‐L1 expression remains unclear in front‐line treatment of HER2‐negative gastric and gastroesophageal junction (GC/GEJ) cancer with PD‐(L)1 therapy. The first PD‐1/CTLA‐4 bispecific antibody (BsAb), cadonilimab, has been approved, but it is unknown if it can extend the PD‐(L)1 regimen to lower PD‐L1 patients.